Please assess the completion status of the following clinical trial:

Trial Title: Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal failure, stage 3 or worse~* Undergoing endovascular procedure with an isotonic, non ionized contrast agent~* Life expectancy at least 4 weeks from date of registration~* Platelets greater than or equal to 100,000/mm3~* Systolic pressure of greater than 90 mm Hg~* No contraindications to N-Ac or contrast agent~* Not at risk for general anesthesia~Exclusion Criteria:~* Acute renal failure~* Undergoing dialysis~* Decompensate cardiac failure~* Pregnant or nursing~* History of clinically significant reactive airway disease~* Receiving non-steroidal anti-inflammatory agent within 24 hours of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1, IV NAC (Type: EXPERIMENTAL): N-acetylcysteine administered intravenously
- 2, IA NAC (Type: EXPERIMENTAL): N-acetylcysteine administered intra-arterial

Based on this trial design, predict the completion outcome and termination type (if applicable).